Mutational analysis and clinical correlation of metastatic colorectal cancer

Cancer

Volumn 120, Issue 10, 2014, Pages 1482-1490

  Russo, Andrea L ^a   Borger, Darrell R ^b   Szymonifka, Jackie ^b   Ryan, David P ^b   Wo, Jennifer Y ^b   Blaszkowsky, Lawrence S ^b   Kwak, Eunice L ^b   Allen, Jill N ^b   Wadlow, Raymond C ^b   Zhu, Andrew X ^b   Murphy, Janet E ^b   Faris, Jason E ^b   Dias Santagata, Dora ^b   Haigis, Kevin M ^b   Ellisen, Leif W ^b   Iafrate, Anthony J ^b   Hong, Theodore S ^b  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BRAF; clinicopathologic; colorectal cancer; mutation; NRAS

Indexed keywords

APC PROTEIN; B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGE; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRAF GENE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CODON; COLON ADENOCARCINOMA; CONTROLLED STUDY; CORRELATIONAL STUDY; DESCENDING COLON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; RECTUM CARCINOMA; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR GENE; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE;

BRAF; CLINICOPATHOLOGIC; COLORECTAL CANCER; MUTATION; NRAS;

ADENOCARCINOMA; ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; GTP PHOSPHOHYDROLASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899918816     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28599     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Hong TS, Clark JW, Haigis KM,. Cancers of the colon and rectum: identical or fraternal twins? Cancer Discov. 2012; 2: 117-121.
3. Kornmann M, Staib L, Wiegel T, et al. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer. Clin Colorectal Cancer. 2013; 12: 54-61.
4. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S,. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol. 2009; 6: 352-366.
5. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28: 466-474.
6. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications [serial online]. PLoS One. 2011; 6: e17948.
7. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010; 2: 146-158.
8. Peeters M, Douillard JY, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol. 2013; 31: 759-765.
9. Imamura Y, Morikawa T, Liao X, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012; 18: 4753-4763.
10. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65: 6063-6069.
11. Irahara N, Baba Y, Nosho K, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010; 19: 157-163.
12. Hacker E, Nagore E, Cerroni L, et al. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations. J Invest Dermatol. 2013; 133: 1027-1033.
13. Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011; 104: 856-862.
14. Berg M, Danielsen SA, Ahlquist T, et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset [serial online]. PLoS One. 2010; 5: e13978.
15. Fearon ER, Vogelstein B,. A genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759-767.
16. Russo A, Bazan V, Iacopetta B, et al. The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005; 23: 7518-7528.
17. Luchtenborg M, Weijenberg MP, Kampman E, et al. Cigarette smoking and colorectal cancer: APC mutations, hMLH1 expression, and GSTM1 and GSTT1 polymorphisms. Am J Epidemiol. 2005; 161: 806-815.
18. Diergaarde B, Vrieling A, van Kraats AA, van Muijen GN, Kok FJ, Kampman E,. Cigarette smoking and genetic alterations in sporadic colon carcinomas. Carcinogenesis. 2003; 24: 565-571.
19. Goss KH, Groden J,. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol. 2000; 18: 1967-1979.
20. Haug U, Poole EM, Xiao L, et al. Glutathione peroxidase tagSNPs: associations with rectal cancer but not with colon cancer. Genes Chromosomes Cancer. 2012; 51: 598-605.
21. Mates IN, Jinga V, Csiki IE, et al. Single nucleotide polymorphisms in colorectal cancer: associations with tumor site and TNM stage. J Gastrointest Liver Dis. 2012; 21: 45-52.
22. Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A,. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol. 2010; 37: 707-718.
23. Sanz-Pamplona R, Cordero D, Berenguer A, et al. Gene expression differences between colon and rectum tumors. Clin Cancer Res. 2011; 17: 7303-7312.
24. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487: 330-337.
25. Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011; 17: 1122-1130.
26. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G,. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis [serial online]. PLoS One. 2012; 7: e47054.
27. Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL,. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer. 2013; 119: 714-721.
28. Iacopetta B,. TP53 mutation in colorectal cancer. Hum Mutat. 2003; 21: 271-276.
29. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012; 30: 2956-2962.
30. Kawamoto Y, Tsuchihara K, Yoshino T, et al. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer. 2012; 107: 340-344.